EP0595910A1 - S- 3-(4(5)-imidazolyl)propyl isothioharnstoffe als selektive h3 histaminrezeptorantagonisten - Google Patents

S- 3-(4(5)-imidazolyl)propyl isothioharnstoffe als selektive h3 histaminrezeptorantagonisten

Info

Publication number
EP0595910A1
EP0595910A1 EP92915736A EP92915736A EP0595910A1 EP 0595910 A1 EP0595910 A1 EP 0595910A1 EP 92915736 A EP92915736 A EP 92915736A EP 92915736 A EP92915736 A EP 92915736A EP 0595910 A1 EP0595910 A1 EP 0595910A1
Authority
EP
European Patent Office
Prior art keywords
isothiourea
histamine
imidazolyl
propyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92915736A
Other languages
English (en)
French (fr)
Inventor
William Parke-Davis Research Unit Howson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP0595910A1 publication Critical patent/EP0595910A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to pharmaceutical compositions comprising an imidazole derivative, their use in the manufacture of medicaments having histamine ⁇ -antagonist activity and a method of blocking histamine ⁇ -receptors by administering them.
  • Histamine a physiologically active compound endogenous in mammals, exerts its action by interacting with certain sites called receptors.
  • One type of receptor is known as a histamine H-j_-receptor (Ash and Schild, Brit. J. Pharmac. Chemother. 22.427 (1966)) and the actions of histamine mediated through these receptors are blocked by H- j _- antagonists such as mepyramine.
  • a second type of receptor is known as the histamine H2 ⁇ receptor (Black et al., Nature 1972, 236, 385) which is not blocked by mepyramine but by H2 ⁇ antagonists such as burimamide or cimetidine.
  • histamine H3 ⁇ receptor A third type of receptor known as the histamine H3 ⁇ receptor has more recently been identified (e.g. Arrang et al.. Nature 1987, 327 , 117 and Van der erf et al., (1989) Trends Pharmacol. Sci. 10, 159) which is stimulated by ⁇ -agonists such as (R)- ⁇ —methylhistamine and blocked by ⁇ -antagonists such as thioperamide.
  • ⁇ -agonists such as (R)- ⁇ —methylhistamine
  • ⁇ -antagonists such as thioperamide
  • US-A-3759944 discloses isothiourea derivatives which are described as acting at histamine receptors other than the H ⁇ -receptor and are of utility in inhibiting certain actions of histamine which are not inhibited by H ⁇ -antagonists such as the inhibition of histamine-stimulated secretion of gastric acid.
  • a particular isothiourea described is S-[3- (4 (5)-imidazolyDpropyl]isothiourea dihydrobromide. This compound is also disclosed in Eur. J. ed. Chem.-Chim. Ther., 21(4), 305-9 (1986) wherein it is described as being a weak partial H ⁇ -agonist and a weak ⁇ -agonist. It has now been discovered that the above named imidazole compound is a highly potent selective histamine H3- antagonist.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and S-[3-(4(5)-imidazolyDpropyl]- isothiourea or a pharmaceutically acceptable salt thereof in an amount sufficient to block selectively histamine H3- receptors.
  • the present invention provides the use of S-[3-(4 (5)-imidazolyDpropyl]isothiourea or a pharmaceutically acceptable salt thereof in the manufacture of a medicament having histamine H ⁇ -antagonist activity.
  • this invention provides a method of blocking histamine ⁇ -receptors in a host in need thereof which comprises administering an effective amount to block said receptors of S-[3-(4(5)-imidazolyDpropyl]isothiourea or a pharmaceutically acceptable salt thereof.
  • Pharmaceutically acceptable salts include those formed with hydrochloric, hydrobromic, sulphuric, phosphoric, acetic, citric, maleic, lactic, ascorbic, fumaric, oxalic, methanesulphonic and ethanesulphonic acids.
  • S-[3-(4(5)-imidazolyDpropyl]isothiourea and its pharmaceutically acceptable salts can be administered in standard manner for example orally, sublingually, parenterally, transdermally, rectally, via inhalation or via buccal administration.
  • S-[3-(4 (5)-imidazolyDpropyl]isothiourea and its pharmaceutically acceptable salts which are active when given orally or via buccal administration can be formulated appropriately in dosage forms such as liquids, syrups, tablets, capsules and lozenges.
  • An oral liquid formulation will generally consist of a suspension or solution of the compound or salt in a liquid carrier for example, ethanol, glycerine or water with a flavouring or colouring agent.
  • composition is in the form of a tablet
  • any pharmaceutical carrier routinely used for preparing solid formulations can be used.
  • examples of such carriers include magnesium stearate, starch, celluloses, lactose and sucrose.
  • any routine encapsulation is suitable, for example using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule
  • any pharmaceutical carrier routinely used for preparing dispersions or suspensions can be considered, for example aqueous gums, celluloses, silicates or oils and are incorporated in a soft gelatin capsule shell.
  • Typical parenteral compositions consist of a solution or suspension of the compound or salt in a sterile aqueous or non-aqueous carrier optionally containing a parenterally acceptable oil or solubilising agent, for example polyethylene glycol, polyvinyl-pyrrolidone, 2-pyrrolidone, cyclodextrin, lecithin, arachis oil, or sesame oil.
  • a parenterally acceptable oil or solubilising agent for example polyethylene glycol, polyvinyl-pyrrolidone, 2-pyrrolidone, cyclodextrin, lecithin, arachis oil, or sesame oil.
  • a typical suppository formulation comprises S-[3-(4(5)- imidazolyDpropyl]isothiourea or a pharmaceutically acceptable salt thereof which is active when administered in this way, with a binding and/or lubricating agent, for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • a binding and/or lubricating agent for example polymeric glycols, gelatins, cocoa-butter or other low melting vegetable waxes or fats or their synthetic analogues.
  • Typical transdermal formulations comprise a conventional aqueous or non-aqueous vehicle, for example - A -
  • a cream, ointment, lotion or paste or are in the form of a medicated plaster, patch or membrane.
  • compositions for inhalation are in the form of a solution, suspension or emulsion that may be administered in the form of an aerosol using a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane, or are in the form of a powder for insufflation.
  • a conventional propellant such as dichlorodifluoromethane or trichlorofluoromethane
  • the composition is in unit dosage form, for example a tablet, capsule or metered aerosol dose, so that the patient may administer to himself a single dose.
  • Each dosage unit for oral administration contains suitably from 0.1 mg to 50 mg, and preferably from 1 mg to 25 mg, and each dosage unit for parenteral administration contains suitably from 0.1 mg to 25 mg, of S-[3-(4(5)- imidazolyDpropyl]isothiourea or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for oral administration is suitably about 0.1 mg to 200 mg, preferably 1 mg to 100 mg, of S-[3-(4(5)-imidazolyDpropyl]isothiourea or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the daily dosage regimen for parenteral administration is suitably about 0.1 mg to 100 mg, for example about 1 mg to 40 mg, of S-[3-(4(5)-imidazolyl)- propyl]isothiourea or a pharmaceutically acceptable salt thereof calculated as the free base.
  • the active ingredient may be administered as required for example from 1 to 4 times a day or by infusion.
  • inhalation dosages are controlled by a valve, are administered as required and for an adult are conveniently in the range 0.1- 5.0 mg of S-[3-(4(5)-imidazolyDpropyl]isothiourea or a pharmaceutically acceptable salt thereof.
  • the compounds of this invention may be co-administered with other pharmaceutically active compounds, for example in combination, concurrently or sequentially.
  • the compounds ' of this invention and the other active compound or compounds are formulated in a pharmaceutical composition.
  • diazepam may be included in pharmaceutical compositions comprising S-[3-(4 (5)-imidazolyDpropyl]- isothiourea.
  • the histamine H3 ⁇ antagonist activity of S-[3-(4(5)- imidazolyDpropyl]isothiourea was assessed by a method similar to that described by Trazoakowski (1987) , J. Pharmacol. Exp. Ther., 243. 874-880.
  • Inhibition of the electrically evoked twitch responses of the guinea-pig ileum by histamine ⁇ -receptor agonists was studied by addition of graded concentrations of (R)- ⁇ methyl-histamine (in volumes of 25 ⁇ l or 79 ⁇ l) to the organ bath in a sequential manner. Each concentration of agonist was washed out of the bath when the response had reached equilibrium. A four minute period was allowed between each addition of the compound. In the antagonist studies a ten minute period was used for the antagonist equilibration time. Antagonist activity was quantified by the ability of the compound to block the inhibitory effect of (R)- ⁇ -methylhistamine on the twitch response.
  • S-[3-(4(5)-imidazolyl)- propyl]isothiourea is a highly potent selective histamine H3- antagonist, being about 1000 times more potent at the histamine ⁇ -receptor than at either the histamine H ⁇ - or H2- receptor.
  • Antagonists of the histamine ⁇ -receptor are believed to stimulate the synthesis and release of neurotransmitters such as histamine and are therefore likely to increase neurotransmitter release in the digestive tract and in the nervous,- cardiovascular and immune systems. They are likely to have a psychotropic action and have utility in cognitive disorders including the treatment of Alzheimer's disease and age-associated memory impairment.
  • a pharmaceutical composition for oral administration is prepared containing:
  • ingredients A substituted lactose or microcrystalline cellose for dibasic calcium phosphate dihydrate if desired
  • B added the ingredients B to the dried granules and compressing the mixture into tablets containing 10 mg, 25 mg or 50 mg of the free base.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP92915736A 1991-07-20 1992-07-16 S- 3-(4(5)-imidazolyl)propyl isothioharnstoffe als selektive h3 histaminrezeptorantagonisten Withdrawn EP0595910A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB919115740A GB9115740D0 (en) 1991-07-20 1991-07-20 Medicaments
GB91157404 1991-07-20
PCT/GB1992/001299 WO1993001812A1 (en) 1991-07-20 1992-07-16 S-(3-(4(5))-imidazolyl)propyl)isothiourea as selective trhistomine h3 receptor antagonist

Publications (1)

Publication Number Publication Date
EP0595910A1 true EP0595910A1 (de) 1994-05-11

Family

ID=10698725

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92915736A Withdrawn EP0595910A1 (de) 1991-07-20 1992-07-16 S- 3-(4(5)-imidazolyl)propyl isothioharnstoffe als selektive h3 histaminrezeptorantagonisten

Country Status (5)

Country Link
EP (1) EP0595910A1 (de)
JP (1) JPH06509109A (de)
AU (1) AU2341192A (de)
GB (1) GB9115740D0 (de)
WO (1) WO1993001812A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505298A (ja) * 1993-11-15 1997-05-27 シェーリング コーポレイション Ｈ▲下３▼‐レセプターアンタゴニストとしてのフェニル‐アルキルイミダゾール
US6290986B1 (en) 1996-10-24 2001-09-18 Pharmaceutical Applications Associates, Llc Method and composition for transdermal administration of pharmacologic agents
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6572880B2 (en) 1996-10-24 2003-06-03 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US6407132B1 (en) 1997-07-25 2002-06-18 James Black Foundation Limited Substituted imidazole derivatives and their use as histamine H3 receptor ligands
US6133291A (en) * 1998-10-16 2000-10-17 Schering Corporation N-(imidazolylalkyl)substituted cyclic amines as histamine-H3 agonists or antagonists
US6211182B1 (en) 1999-03-08 2001-04-03 Schering Corporation Imidazole compounds substituted with a six or seven membered heterocyclic ring containing two nitrogen atoms
DE19940130A1 (de) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung
AU2001292730A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
AU2001292723A1 (en) 2000-09-20 2002-04-02 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
WO2002024657A2 (en) 2000-09-20 2002-03-28 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
CA2422729A1 (en) 2000-09-20 2002-06-06 Schering Corporation Substituted imidazoles as dual histamine h1 and h3 agonists or antagonists
AU2002253929A1 (en) 2001-02-08 2002-09-24 Schering Corporation Use of dual h3/m2 antagonists with a bipiperidinic structure in the treatment of cognition deficit disorders
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
WO2004098591A2 (en) * 2003-05-05 2004-11-18 Probiodrug Ag Inhibitors of glutaminyl cyclase and their use in the treatment of neurological diseases
EP1961416B1 (de) 2003-05-05 2013-01-23 Probiodrug AG Verwendung von Hemmern von Glutaminylcyclase zur Behandlung von Rheumatoider Arthritis, Psoriasis oder Atherosklerose
BRPI0415409A (pt) 2003-10-15 2006-12-05 Probiodrug Ag uso de efetuadores de ciclases de glutaminila e glutamato
GB0324897D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
CA2554809C (en) 2004-02-05 2014-04-29 Probiodrug Ag Novel n-alkyl thiourea- and thioamide-substituted imidazolyl inhibitors of glutaminyl cyclase
US20160022751A1 (en) * 2014-07-23 2016-01-28 Gangneung-Wonju National University Industry Academy Cooperation Group Novel composition for treating alzheimer's disease and improving cognitive function of alzheimer's patients

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759944A (en) * 1970-10-14 1973-09-18 Smith Kline French Lab Isothioureas and their derivatives
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
GB8916947D0 (en) * 1989-07-25 1989-09-13 Smith Kline French Lab Medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9301812A1 *

Also Published As

Publication number Publication date
JPH06509109A (ja) 1994-10-13
WO1993001812A1 (en) 1993-02-04
AU2341192A (en) 1993-02-23
GB9115740D0 (en) 1991-09-04

Similar Documents

Publication Publication Date Title
EP0595910A1 (de) S- 3-(4(5)-imidazolyl)propyl isothioharnstoffe als selektive h3 histaminrezeptorantagonisten
US4753789A (en) Method for treating nausea and vomiting
EP0188081B1 (de) Verwendung von Paroxetine zur Herstellung eines Arzneimittel zur Behandlung von Obesität
EP0420396B1 (de) Imidazol-Derivate als Histamin-H3-Agonisten
HUP9904362A2 (hu) Eljárás felső légúti allergiás tünetek kezelésére hisztamin H1 és H3 receptor-antagonisták kombinációjával
US5578632A (en) Medicaments for the treatment of gastrointestinal dysfunction
US4952410A (en) Pharmaceutical products of moxonidine and hydrochlorothiazide
JPS615017A (ja) 抗潰瘍組成物
US4861784A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
US4241087A (en) Dysmenorrhea treatment
JPS6019893B2 (ja) 抗潰瘍剤
JPS6315246B2 (de)
EP0254068B1 (de) Therapeutisches Mittel für Gastritis
US3993778A (en) Anti-ulcerogenic pharmaceutical compositions containing a 2-amino-3,5-dibromo-benzylamine and method of use
CA2264172A1 (en) Remedies for allergic dermatitis
JP3254712B2 (ja) 医薬組成物
JPS6366285B2 (de)
WO1994014431A1 (en) Gastrocytoprotective pharmaceutical composition and process for the preparation thereof
GB2057874A (en) Compositions containing azo compounds and use thereof for therapeutic treatment
US5238946A (en) Therapeutic agent for gastritis
US3957992A (en) Inhibition of gastric acid secretion with 2-pyridyl-perimidine
CA1060344A (en) Antihypertonic agent
US4529731A (en) Thiadiazolediamine derivative with histamine H-2 receptor inhibiting properties
GB1573595A (en) Antihypertensive compositions
IE43955B1 (en) Pharmaceutical composition and dosage units thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19970201